

Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis

NCT05246267

Status RECRUITING
Sponsor Montefiore Medical Center
Enrollment 60 participants

Key Eligibility Criteria

Inclusion (4)

- Patients with physician-diagnosed CRSwNP, with or without comorbid asthma that meet indication criteria for FDA-approved use of Dupilumab.
- Patients aged 18 years and older.
- Patient willing to provide consent to be a participant in the study.
- Patients with insurance that allows Dupilumab coverage or Dupilumab coverage obtained through "Dupixent MyWay Program"

Exclusion (9)

- Age under 18
- Suspected or diagnosed allergic fungal rhinosinusitis.
- Suspected or diagnosed cystic fibrosis.
- Dupilumab coverage denied through insurance or "Dupixent MyWay Program"
- Patients who required a steroid taper in the preceding 30 days. However, patients on chronic steroids less or equal to 20 mg of prednisone daily, are eligible.
- ... and 4 more (see full listing online)

Locations (1 total)

Montefiore Medical Center, The Bronx, New York, United States